Avid Bioservices, Inc. (CDMO) News
Filter CDMO News Items
CDMO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest CDMO News From Around the Web
Below are the latest news stories about AVID BIOSERVICES INC that investors may wish to consider to help them evaluate CDMO as an investment opportunity.
Avid Bioservices, Inc. (NASDAQ:CDMO) Q2 2023 Earnings Call TranscriptAvid Bioservices, Inc. (NASDAQ:CDMO) Q2 2023 Earnings Call Transcript December 6, 2022 Operator: Good day, ladies and gentlemen. And welcome to the Avid Bioservices Second Quarter Fiscal 2023 Financial Results Conference Call. At this time all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will follow at that […] |
Avid Bioservices Second Quarter 2023 Earnings: Revenues Beat Expectations, EPS LagsAvid Bioservices ( NASDAQ:CDMO ) Second Quarter 2023 Results Key Financial Results Revenue: US$34.8m (up 33% from 2Q... |
Avid Bioservices (CDMO) Reports Q2 Loss, Tops Revenue EstimatesAvid Bioservices (CDMO) delivered earnings and revenue surprises of 0% and 12.12%, respectively, for the quarter ended October 2022. Do the numbers hold clues to what lies ahead for the stock? |
Edited Transcript of CDMO.OQ earnings conference call or presentation 6-Dec-22 9:30pm GMTQ2 2023 Avid Bioservices Inc Earnings Call |
Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2022 and Recent Developments-- Recorded Second Quarter Revenue of $34.8 Million -- -- Signed $26 Million in Net New Business Orders Resulting in a Backlog of $147 Million, an Increase of 23% Year-Over-Year -- -- Mammalian Cell Facilities and Cell and Gene Therapy Facility Expansions Continue on Schedule -- -- Revenue Guidance for Fiscal 2023 Increased to $145 to $150 Million -- TUSTIN, Calif., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturin |
Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2023 After Market Close on December 6, 2022TUSTIN, Calif., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the second quarter of fiscal year 2023 on December 6, 2022 after market close and will host a webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Members |
Avid Bioservices (NASDAQ:CDMO) jumps 12% this week, though earnings growth is still tracking behind five-year shareholder returnsAvid Bioservices, Inc. ( NASDAQ:CDMO ) shareholders might be concerned after seeing the share price drop 23% in the... |
Avid Bioservices Appoints Oksana Lukash as Vice President, PeopleTUSTIN, Calif., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced the appointment of Oksana Lukash, as vice president, people. Ms. Lukash has more than 20 years of human resources experience with both established and entrepreneurial org |
Avid Bioservices to Participate in the Credit Suisse 31st Annual Healthcare ConferenceTUSTIN, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company will participate in the Credit Suisse 31st Annual Healthcare Conference. Nick Green, president and chief executive officer of Avid Bioservices, will deli |
Does Avid Bioservices (CDMO) Have the Potential to Rally 61% as Wall Street Analysts Expect?The consensus price target hints at a 60.5% upside potential for Avid Bioservices (CDMO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |